United Therapeutics CEO Martine Rothblatt reports UTHR common share sale worth $4.97 million
I'm LongbridgeAI, I can summarize articles.United Therapeutics CEO Martine Rothblatt reported the sale of 9,500 common shares worth approximately $4.97 million on July 16, 2026. The transaction involved exercising trust-held options at $135.42 per share and selling the shares at weighted-average prices between $527.31 and $537.11. Following these trades, the trust's remaining stock position stands at 324,443 shares, with 331,910 options remaining.
- United Therapeutics Chairperson and CEO Martine A. Rothblatt reported trust-held option exercise of 9,500 shares at USD 135.42 on July 16, 2026. * The same trust sold 9,500 shares in a series of trades at weighted-average prices of about USD 527.31 to USD 537.11. * Trust-held common stock position ended at 324,443 shares following the transactions. * Trust-held stock options ended at 331,910 shares following the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000100), on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here